📣 Creators, Exciting News!
Gate Square Certified Creator Application Is Now Live!
How to apply:
1️⃣ Open App → Tap [Square] at the bottom → Click your avatar in the top right
2️⃣ Tap [Get Certified] under your avatar
3️⃣ Once approved, you’ll get an exclusive verified badge that highlights your credibility and expertise!
Note: You need to update App to version 7.25.0 or above to apply.
The application channel is now open to KOLs, project teams, media, and business partners!
Super low threshold, just 500 followers + active posting to apply!
At Gate Square, everyone can be a community leader! �
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.